{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001117",
    "licUnit": "1",
    "validDate": "2029-12-17 00:00:00.000",
    "issueDate": "2019-12-17 00:00:00.000",
    "oriIssueDate": "2019-12-17",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000111705",
    "prodNameC": "艾法施注射液",
    "prodNameE": "MVASI Solution for Injection",
    "indicationsName": [
        "1.轉移性大腸直腸癌(mCRC)：(1)與含有5-fluorouracil為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。(2)與含有5-fluorouracil\/leucovorin\/oxaliplatin的化學療法合併使用，可以作為先前接受過以 fluoropyrimidine為基礎的化學療法無效且未曾接受過bevacizumab治療的轉移性大腸或直腸癌病人的治療。(3)與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin-為基礎的化學療法合併使用，可以做為第一線已接受過以MVASI併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。\r\n2.轉移性乳癌(mBC)：與paclitaxel合併使用，可以做為HER2(-)轉移性乳癌病人的第一線治療。\r\n3.惡性神經膠質瘤(WHO第4級)-神經膠母細胞瘤：單獨使用可用於治療曾接受標準放射線治療且含temozolomide在內之化學藥物治療失敗之多型性神經膠母細胞瘤(Glioblastoma multiforme)復發之成人病人。\r\n4.晚期、轉移性或復發性非鱗狀非小細胞肺癌(NSCLC)：(1)與carboplatin及paclitaxel合併使用，可以作為無法切除的晚期、轉移性或復發性非鱗狀非小細胞肺癌病人的第一線治療。(2)併用erlotinib，可作為無法手術切除的晚期、轉移性或復發性且帶有表皮生長因子受體(EGFR)活化性突變的非鱗狀非小細胞肺癌病人的第一線治療。\r\n5.持續性、復發性或轉移性之子宮頸癌(Persistent, Recurrent, or Metastatic Cervical Cancer)：(1)與paclitaxel及cisplatin合併使用可用於治療持續性、復發性或轉移性之子宮頸癌。(2)與paclitaxel及topotecan合併使用可用於無法接受含鉑類藥物治療(platinum therapy)病人之持續性、復發性或轉移性子宮頸癌。\r\n6.卵巢上皮細胞、輸管或原發性腹膜癌(Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer)：(1)與carboplatin及paclitaxel合併使用，接著單獨使用MVASI，可以做為第三期或第四期卵巢上皮細胞、輸卵管或原發性腹膜癌病人接受初次手術切除後之治療。(2)與carboplatin及gemcitabine合併使用，可以做為曾接受過第一線含鉑類藥物(platinum-based)化學治療間隔至少6個月再復發（即，對含鉑藥物具感受性），且未曾接受過bevacizumab或其他血管內皮細胞生長因子(VEGF)抑制劑或血管內皮細胞生長因子接受器之標靶藥物(VEGF receptor-targeted agents)治療之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。(3)與carboplatin及paclitaxel合併使用，接著單獨使用MVASI治療，可以做為對含鉑藥物具感受性之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。(4)併用paclitaxel、topotecan或pegylated liposomal doxorubicin可以做為接受過含鉑類藥物(platinum-based)化療治療後6個月內再復發（即，對含鉑藥物具抗藥性）、之前接受不超過2種化療療程且未曾接受過bevacizumab或其他血管內皮細胞生長因子(VEGF)抑制劑或血管內皮細胞生長因子接受器之標靶藥物(VEGF receptor-targeted agents)之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。"
    ],
    "does": "227D",
    "packageUnit": [
        {
            "packageSpec": "4毫升、16毫升玻璃小瓶，100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "D",
    "mainCategory": "D",
    "drBaseId": "02A39883-6758-4AFB-979C-8AE7DA9C0B36",
    "subCategory": [],
    "ingredientsDesc": [
        "BEVACIZUMAB"
    ],
    "restraintItemsCode": [
        "02 輸 入",
        "07 新藥監視",
        "1D 須執行風險管理計畫",
        "5E 已執行國內臨床試驗",
        "67 成品已完成元素不純物評估(Option 1、2a、2b)",
        "91 生物相似性藥品"
    ],
    "applicantName": "台灣安進藥品有限公司 ",
    "applicantAddr": "臺北市信義區松仁路100號13樓之1、之2",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2024-12-17",
    "licidNew": null,
    "licidOld": null,
    "manuImportDesc": "廠商未登錄資料",
    "licManuImport": "2",
    "factoryDtoList": [
        {
            "id": "4A23DB1D-FF97-4453-9D53-57AA035CC2D2",
            "factoryCode": "1",
            "factoryName": "AMGEN MANUFACTURING LIMITED LLC",
            "factoryAddr": "STATE ROAD 31, KM 24.6 JUNCOS, PUERTO RICO 00777-4060",
            "factoryCompanyAddr": "",
            "countryCode": "PR",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FPR0062100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "7A956216-4A64-4F6A-943E-7BA0BBAA5800",
            "factoryCode": "2",
            "factoryName": "AMGEN INC.",
            "factoryAddr": "ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 U.S.A.",
            "factoryCompanyAddr": null,
            "countryCode": "US",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0325000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "B2D02F4F-64AC-40FF-ABBC-F2194AC23B66",
            "factoryCode": "2",
            "factoryName": "IMMUNEX RHODE ISLAND CORPORATION",
            "factoryAddr": "40 TECHNOLOGY WAY, WEST GREENWICH RHODE ISLAND 02817, USA",
            "factoryCompanyAddr": "",
            "countryCode": "US",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0866000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013000800",
            "ingredientsName": "BEVACIZUMAB",
            "ingredientsDesc": "BEVACIZUMAB",
            "concentDesc": "",
            "concent": "25.000000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FG01"
        }
    ],
    "licBaseId": "AAE8CCBB-72C8-43E6-91E8-883AEF710DA7"
}